Compare Hims and Hers Health Inc (HIMS) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs OneSpan Inc — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while OneSpan Inc trades at $18.22 (market cap $662.97M). The key difference: Hims and Hers Health Inc is far larger — about 9.9× OneSpan Inc's market cap, and OneSpan Inc pays a 2.89% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and OneSpan Inc for 18 Days on average.
| HIMS | OSPN | |
|---|---|---|
Market Cap | $6.55B | $662.97M |
Volume | 14,842,814 | 616,882 |
Sector | Health | Technology |
52-Week High | $62.76 | $18.42 |
52-Week Low | $14.52 | $10.15 |
Typical Hold Time | 21 Days | 18 Days |
Enterprise Value | $7.25B | $632.05M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, reflecting bearish technical signals and negative earnings surprises in recent quarters. The company reported strong revenue growth to $2.35 billion in 2025 but swung to a net loss of -$142 million in 2026, with profitability metrics deteriorating. Multiple securities class action lawsuits filed in October 2026 create significant legal overhangs, while analyst consensus remains cautiously optimistic with a $32.17 price target despite mixed fundamental performance.
The outlook is clouded by legal risks and profitability challenges, though the 15% upside to consensus target suggests potential recovery if execution improves. Key risks include ongoing litigation outcomes and the company's ability to return to sustainable profitability amid competitive pressures in the telehealth sector.
OneSpan (OSPN) trades at $18.01, up 1.75% with strong technical momentum and consistent earnings beats. The stock shows bullish moving average signals while maintaining solid fundamentals including 27.76% net margins and attractive valuation at 10.16 P/E. Recent Q2 2026 results exceeded expectations with $0.30 EPS versus $0.231 estimate, supporting the positive analyst sentiment.
Outlook remains favorable given the unanimous analyst buy/hold consensus and recent product innovation with DigipassONE launch. Key risks include declining cash flow trends and competitive pressures in the authentication technology space. The stock's current valuation and earnings momentum provide upside potential, though investors should monitor execution on subscription revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
